5.10
price down icon1.16%   -0.06
after-market 시간 외 거래: 5.21 0.11 +2.16%
loading
전일 마감가:
$5.16
열려 있는:
$5.25
하루 거래량:
2.46M
Relative Volume:
1.14
시가총액:
$280.24M
수익:
$3.64M
순이익/손실:
$-87.37M
주가수익비율:
-1.2409
EPS:
-4.11
순현금흐름:
$-86.46M
1주 성능:
+2.82%
1개월 성능:
+3.45%
6개월 성능:
-5.38%
1년 성능:
+53.61%
1일 변동 폭
Value
$5.05
$5.56
1주일 범위
Value
$4.795
$5.57
52주 변동 폭
Value
$2.10
$9.10

Verastem Inc Stock (VSTM) Company Profile

Name
명칭
Verastem Inc
Name
전화
(781) 292-4200
Name
주소
117 KENDRICK STREET, NEEDHAM, MA
Name
직원
78
Name
트위터
@VerastemOncolog
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
VSTM's Discussions on Twitter

VSTM을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VSTM
Verastem Inc
5.10 272.55M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Verastem Inc Stock (VSTM) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-10 개시 Jefferies Buy
2025-03-24 재확인 H.C. Wainwright Buy
2024-12-31 재확인 BTIG Research Buy
2024-09-30 개시 Guggenheim Buy
2023-11-21 재개 BTIG Research Buy
2023-09-27 개시 B. Riley Securities Buy
2023-06-15 업그레이드 Mizuho Neutral → Buy
2022-09-07 재개 Alliance Global Partners Buy
2022-04-29 재개 Cantor Fitzgerald Overweight
2022-04-14 개시 RBC Capital Mkts Outperform
2022-03-09 개시 Truist Buy
2021-07-01 개시 Alliance Global Partners Buy
2021-05-24 업그레이드 BTIG Research Neutral → Buy
2019-06-20 다운그레이드 BTIG Research Buy → Neutral
2019-05-10 다운그레이드 Raymond James Outperform → Mkt Perform
2018-07-13 개시 BTIG Research Buy
2018-05-02 개시 Seaport Global Securities Buy
2018-03-08 개시 B. Riley FBR, Inc. Buy
2017-09-07 재확인 H.C. Wainwright Buy
2017-04-13 개시 Oppenheimer Outperform
2017-03-24 재확인 H.C. Wainwright Buy
2015-09-29 다운그레이드 Cantor Fitzgerald Buy → Hold
2015-09-29 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 다운그레이드 Jefferies Buy → Hold
2015-09-29 다운그레이드 Raymond James Strong Buy → Outperform
2015-09-28 다운그레이드 Mizuho Buy → Neutral
2015-09-28 다운그레이드 ROTH Capital Buy → Neutral
2015-09-09 개시 Raymond James Strong Buy
2015-05-12 재확인 UBS Buy
2015-04-08 개시 H.C. Wainwright Buy
2015-01-23 재확인 ROTH Capital Buy
2014-07-08 재개 Oppenheimer Perform
2014-02-11 개시 Mizuho Buy
모두보기

Verastem Inc 주식(VSTM)의 최신 뉴스

pulisher
01:40 AM

What analysts say about Verastem Inc. stockPowerful market insights - Autocar Professional

01:40 AM
pulisher
11:58 AM

What drives Verastem Inc. stock priceBreakthrough stock performance - Autocar Professional

11:58 AM
pulisher
Jul 20, 2025

Verastem Inc. Stock Analysis and ForecastFree Market Dynamics Reports - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Is Verastem Inc. a good long term investmentConsistent high-yield stocks - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 18, 2025

Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 16, 2025

Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance

Jul 14, 2025
pulisher
Jul 11, 2025

Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance

Jul 11, 2025
pulisher
Jul 10, 2025

KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight - Barchart.com

Jul 10, 2025
pulisher
Jul 08, 2025

Verastem Oncology's Talent Incentives: Balancing Equity Dilution and Growth - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Verastem Oncology announces inducement grants under Nasdaq listing rule - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Verastem Oncology Awards 45,000 Share Options at $4.29 Each to Expand Cancer Drug Development Team - Stock Titan

Jul 08, 2025
pulisher
Jul 04, 2025

Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment - TipRanks

Jul 04, 2025
pulisher
Jul 02, 2025

Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

How the (VSTM) price action is used to our Advantage - news.stocktradersdaily.com

Jul 01, 2025
pulisher
Jun 30, 2025

Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer - TipRanks

Jun 30, 2025
pulisher
Jun 28, 2025

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jun 28, 2025
pulisher
Jun 26, 2025

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha

Jun 26, 2025
pulisher
Jun 25, 2025

Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VSTM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - BioSpace

Jun 25, 2025
pulisher
Jun 24, 2025

Verastem Executives Sell Shares to Meet Tax Obligations - TradingView

Jun 24, 2025
pulisher
Jun 20, 2025

Verastem CEO Paterson sells $1.8k in shares By Investing.com - Investing.com Canada

Jun 20, 2025
pulisher
Jun 13, 2025

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges - Investing.com

Jun 13, 2025
pulisher
Jun 10, 2025

(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 06, 2025

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish - MSN

Jun 06, 2025
pulisher
Jun 03, 2025

ASCO 2025: Verastem has positive cancer data but stock sags - BioWorld MedTech

Jun 03, 2025
pulisher
Jun 03, 2025

Cantor Fitzgerald reiterates overweight rating on Verastem stock By Investing.com - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 02, 2025

Transcript : Verastem, Inc.Special Call - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

What's Going On With Verastem Oncology Stock On Monday? - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet T - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Verastem (VSTM) Reports Promising Results in GFH375 Trial for Ca - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Verastem (VSTM) Reports Promising Results in GFH375 Trial for Cancer Treatment | VSTM Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor | VSTM Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Verastem reports promising cancer drug trial results By Investing.com - Investing.com Nigeria

Jun 02, 2025

Verastem Inc (VSTM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):